DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Chronic Pain Management
  4. Research Highlights/News
  5. 2022 Chronic Pain Management Research Program

Chronic Pain Management

NEWS RELEASE

Released: March 9, 2022

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Chronic Pain Management Research Program
Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)

The Fiscal Year 2022 (FY22) Defense Appropriations Bill has not been signed into law. Although FY22 funds have not been appropriated for the Chronic Pain Management Research Program (CPMRP), the CPMRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the Government.

The FY22 Defense Appropriations Act is anticipated to provide funding for the Chronic Pain Management Research Program (CPMRP) to support and promote innovative, high-impact research to prevent the development and improve the management of chronic pain, with specific emphasis on the utilization and implementation of non-opioid therapies or non-addictive complementary methods. Per the FY19 CPMRP congressional appropriation, chronic pain is defined as a pain that occurs on at least half the days for 6 months or more, and which can be caused by issues including, but not limited to: combat- and training-related physical or mental stress and trauma, migraines and chronic headaches, traumatic brain injury, arthritis, muscular-skeletal conditions, neurological disease, tick and vector-borne disease, other insect-transmitted or tropical disease, and cancer. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The CPMRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY22 CPMRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.

Applications submitted to the FY22 CPMRP must address one or more of the following focus areas:

  • Clinical Exploration Award
    • Chronification of pain
    • Effectiveness or observational studies of novel treatments or untested techniques/approaches/pathways to chronic pain management
  • Investigator-Initiated Research Award
    • Chronification of pain
    • Development of non-opioid therapies and methods for the treatment of chronic pain
    • Effectiveness or observational studies of novel treatments or untested techniques/approaches/pathways to chronic pain management
  • Translational Research Award
    • Comparative effectiveness studies (for evidence-based, efficacious interventions to manage or prevent chronic pain)
    • Implementation science (for evidence-based, efficacious interventions to manage or prevent chronic pain)
    • Observational studies related to chronic pain


Award Mechanism Eligibility Key Mechanism Elements Funding
Clinical Exploration Award Independent Investigators at all levels
  • Supports proof-of-principle pilot studies, clinical trials, and correlative studies, particularly those including complementary and integrative health methods.
  • Preliminary and/or published data are not required, but the scientific rationale for the proposed study must be clearly articulated.
  • Should be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.
  • Studies evaluating opioid-based therapeutic interventions are not allowed.
  • Maximum funding of $250,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 2 years.
Investigator-Initiated Research Award Investigators at or above the level of Assistant Professor (or equivalent)
  • Emphasis on innovative and impactful research.
  • Must include preliminary and/or published data or clinical observations that originated from the research team that support the rationale for the proposed study.
  • Should be relevant to active duty Service Members, Veterans, military beneficiaries, and/or the American public.
  • Multidisciplinary collaborations are encouraged.
  • Partnering Principal Investigator (PI) Option available.
  • Clinical trials are not allowed.
  • Maximum funding of $900,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 4 years.
Translational Research Award Investigators at or above the level of Assistant Professor (or equivalent)
  • Supports acceleration of evidence-based ideas and research into clinical applications (e.g., healthcare products, technologies, practice guidelines, models of care).
  • Must include preliminary and/or published data collected by the research team that support the rationale for the proposed study.
  • Key stakeholder engagement throughout the research process is highly encouraged.
  • Partnering PI Option available.
  • Studies evaluating opioid-based therapeutic interventions are not allowed.
  • Maximum funding of $1,400,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the CPMRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Thursday, December 5, 2024